Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
Identifieur interne : 003504 ( Main/Exploration ); précédent : 003503; suivant : 003505Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
Auteurs : Kenichi Akaji [Japon] ; Hiroyuki Konno [Japon] ; Mari Onozuka [Japon] ; Ayumi Makino [Japon] ; Hiroyuki Saito [Japon] ; Kazuto Nosaka [Japon]Source :
- Bioorganic & medicinal chemistry [ 0968-0896 ] ; 2008.
Descripteurs français
- KwdFr :
- Aldéhydes (pharmacologie), Aldéhydes (synthèse chimique), Conformation des protéines, Cysteine endopeptidases (génétique), Cysteine endopeptidases (métabolisme), Données de séquences moléculaires, Humains, Hydrolyse, Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (synthèse chimique), Maturation post-traductionnelle des protéines, Modèles moléculaires, Mutation (génétique), Protéines virales (antagonistes et inhibiteurs), Protéines virales (génétique), Protéines virales (métabolisme), Sites de fixation, Spectrométrie de masse MALDI, Spécificité du substrat, Structure moléculaire, Syndrome respiratoire aigu sévère (génétique), Séquence d'acides aminés, Virus du SRAS (enzymologie), Virus du SRAS (génétique), Virus du SRAS (métabolisme).
- MESH :
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Virus du SRAS.
- génétique : Cysteine endopeptidases, Mutation, Protéines virales, Syndrome respiratoire aigu sévère, Virus du SRAS.
- métabolisme : Cysteine endopeptidases, Protéines virales, Virus du SRAS.
- pharmacologie : Aldéhydes, Inhibiteurs de protéases.
- synthèse chimique : Aldéhydes, Inhibiteurs de protéases.
- Pascal (Inist)
- Conformation des protéines, Données de séquences moléculaires, Humains, Hydrolyse, Maturation post-traductionnelle des protéines, Modèles moléculaires, Peptide, Aldéhyde, Inhibiteur protease, Mutation, Cysteine endopeptidases, Sites de fixation, Spectrométrie de masse MALDI, Spécificité du substrat, Structure moléculaire, Séquence d'acides aminés, Virus syndrome respiratoire aigu sévère, Résistance hydrolyse, Activité biologique, Synthèse chimique, Synthèse peptidique, In vitro, Inhibiteur enzyme, Glutamique acide(acétylthréonyl-séryl-alanyl-valyl-leucyl-1-désoxy).
English descriptors
- KwdEn :
- Aldehyde, Aldehydes (chemical synthesis), Aldehydes (pharmacology), Amino Acid Sequence, Binding Sites, Biological activity, Chemical synthesis, Cysteine Endopeptidases (genetics), Cysteine Endopeptidases (metabolism), Cysteine endopeptidases, Enzyme inhibitor, Humans, Hydrolysis, Hydrolysis resistance, In vitro, Models, Molecular, Molecular Sequence Data, Molecular Structure, Mutation, Mutation (genetics), Peptide synthesis, Peptides, Protease Inhibitors (chemical synthesis), Protease Inhibitors (pharmacology), Protease inhibitor, Protein Conformation, Protein Processing, Post-Translational, SARS Virus (enzymology), SARS Virus (genetics), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (genetics), Severe acute respiratory syndrome virus, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Substrate Specificity, Viral Proteins (antagonists & inhibitors), Viral Proteins (genetics), Viral Proteins (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemical synthesis : Aldehydes, Protease Inhibitors.
- chemical , genetics : Cysteine Endopeptidases, Viral Proteins.
- chemical , metabolism : Cysteine Endopeptidases, Viral Proteins.
- chemical , pharmacology : Aldehydes, Protease Inhibitors.
- enzymology : SARS Virus.
- genetics : Mutation, SARS Virus, Severe Acute Respiratory Syndrome.
- metabolism : SARS Virus.
- Amino Acid Sequence, Binding Sites, Humans, Hydrolysis, Models, Molecular, Molecular Sequence Data, Molecular Structure, Protein Conformation, Protein Processing, Post-Translational, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Substrate Specificity.
Abstract
The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with lle at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a Km of 33.8 μM and kcat of 4753 s-1. Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 106. Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000237
- to stream PascalFrancis, to step Curation: 000751
- to stream PascalFrancis, to step Checkpoint: 000284
- to stream Main, to step Merge: 003610
- to stream Pmc, to step Corpus: 000E47
- to stream Pmc, to step Curation: 000E47
- to stream Pmc, to step Checkpoint: 000E25
- to stream PubMed, to step Corpus: 001A54
- to stream PubMed, to step Curation: 001A54
- to stream PubMed, to step Checkpoint: 001B34
- to stream Ncbi, to step Merge: 001D64
- to stream Ncbi, to step Curation: 001D64
- to stream Ncbi, to step Checkpoint: 001D64
- to stream Main, to step Merge: 003202
- to stream Main, to step Curation: 003504
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant</title><author><name sortKey="Akaji, Kenichi" sort="Akaji, Kenichi" uniqKey="Akaji K" first="Kenichi" last="Akaji">Kenichi Akaji</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Konno, Hiroyuki" sort="Konno, Hiroyuki" uniqKey="Konno H" first="Hiroyuki" last="Konno">Hiroyuki Konno</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Onozuka, Mari" sort="Onozuka, Mari" uniqKey="Onozuka M" first="Mari" last="Onozuka">Mari Onozuka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Makino, Ayumi" sort="Makino, Ayumi" uniqKey="Makino A" first="Ayumi" last="Makino">Ayumi Makino</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biophysical Chemistry, Kobe Pharmaceutical University</s1><s2>Kobe 658-8558</s2><s3>JPN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kobe 658-8558</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Hiroyuki" sort="Saito, Hiroyuki" uniqKey="Saito H" first="Hiroyuki" last="Saito">Hiroyuki Saito</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biophysical Chemistry, Kobe Pharmaceutical University</s1><s2>Kobe 658-8558</s2><s3>JPN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kobe 658-8558</wicri:noRegion></affiliation></author><author><name sortKey="Nosaka, Kazuto" sort="Nosaka, Kazuto" uniqKey="Nosaka K" first="Kazuto" last="Nosaka">Kazuto Nosaka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0041831</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 09-0041831 INIST</idno><idno type="RBID">Pascal:09-0041831</idno><idno type="wicri:Area/PascalFrancis/Corpus">000237</idno><idno type="wicri:Area/PascalFrancis/Curation">000751</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000284</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000284</idno><idno type="wicri:doubleKey">0968-0896:2008:Akaji K:evaluation:of:peptide</idno><idno type="wicri:Area/Main/Merge">003610</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126698</idno><idno type="RBID">PMC:7126698</idno><idno type="wicri:Area/Pmc/Corpus">000E47</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E47</idno><idno type="wicri:Area/Pmc/Curation">000E47</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E47</idno><idno type="wicri:Area/Pmc/Checkpoint">000E25</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E25</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18845442</idno><idno type="wicri:Area/PubMed/Corpus">001A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A54</idno><idno type="wicri:Area/PubMed/Curation">001A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A54</idno><idno type="wicri:Area/PubMed/Checkpoint">001B34</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B34</idno><idno type="wicri:Area/Ncbi/Merge">001D64</idno><idno type="wicri:Area/Ncbi/Curation">001D64</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D64</idno><idno type="wicri:doubleKey">0968-0896:2008:Akaji K:evaluation:of:peptide</idno><idno type="wicri:Area/Main/Merge">003202</idno><idno type="wicri:Area/Main/Curation">003504</idno><idno type="wicri:Area/Main/Exploration">003504</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant</title><author><name sortKey="Akaji, Kenichi" sort="Akaji, Kenichi" uniqKey="Akaji K" first="Kenichi" last="Akaji">Kenichi Akaji</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Konno, Hiroyuki" sort="Konno, Hiroyuki" uniqKey="Konno H" first="Hiroyuki" last="Konno">Hiroyuki Konno</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Onozuka, Mari" sort="Onozuka, Mari" uniqKey="Onozuka M" first="Mari" last="Onozuka">Mari Onozuka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author><author><name sortKey="Makino, Ayumi" sort="Makino, Ayumi" uniqKey="Makino A" first="Ayumi" last="Makino">Ayumi Makino</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biophysical Chemistry, Kobe Pharmaceutical University</s1><s2>Kobe 658-8558</s2><s3>JPN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kobe 658-8558</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Hiroyuki" sort="Saito, Hiroyuki" uniqKey="Saito H" first="Hiroyuki" last="Saito">Hiroyuki Saito</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biophysical Chemistry, Kobe Pharmaceutical University</s1><s2>Kobe 658-8558</s2><s3>JPN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kobe 658-8558</wicri:noRegion></affiliation></author><author><name sortKey="Nosaka, Kazuto" sort="Nosaka, Kazuto" uniqKey="Nosaka K" first="Kazuto" last="Nosaka">Kazuto Nosaka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</s1><s2>Kita-ku, Kyoto 603-8334</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kita-ku, Kyoto 603-8334</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Bioorganic & medicinal chemistry</title><title level="j" type="abbreviated">Bioorg. med. chem.</title><idno type="ISSN">0968-0896</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry</title><title level="j" type="abbreviated">Bioorg. med. chem.</title><idno type="ISSN">0968-0896</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aldehyde</term><term>Aldehydes (chemical synthesis)</term><term>Aldehydes (pharmacology)</term><term>Amino Acid Sequence</term><term>Binding Sites</term><term>Biological activity</term><term>Chemical synthesis</term><term>Cysteine Endopeptidases (genetics)</term><term>Cysteine Endopeptidases (metabolism)</term><term>Cysteine endopeptidases</term><term>Enzyme inhibitor</term><term>Humans</term><term>Hydrolysis</term><term>Hydrolysis resistance</term><term>In vitro</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Molecular Structure</term><term>Mutation</term><term>Mutation (genetics)</term><term>Peptide synthesis</term><term>Peptides</term><term>Protease Inhibitors (chemical synthesis)</term><term>Protease Inhibitors (pharmacology)</term><term>Protease inhibitor</term><term>Protein Conformation</term><term>Protein Processing, Post-Translational</term><term>SARS Virus (enzymology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (genetics)</term><term>Severe acute respiratory syndrome virus</term><term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term><term>Substrate Specificity</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (genetics)</term><term>Viral Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aldéhydes (pharmacologie)</term><term>Aldéhydes (synthèse chimique)</term><term>Conformation des protéines</term><term>Cysteine endopeptidases (génétique)</term><term>Cysteine endopeptidases (métabolisme)</term><term>Données de séquences moléculaires</term><term>Humains</term><term>Hydrolyse</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Inhibiteurs de protéases (synthèse chimique)</term><term>Maturation post-traductionnelle des protéines</term><term>Modèles moléculaires</term><term>Mutation (génétique)</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Protéines virales (génétique)</term><term>Protéines virales (métabolisme)</term><term>Sites de fixation</term><term>Spectrométrie de masse MALDI</term><term>Spécificité du substrat</term><term>Structure moléculaire</term><term>Syndrome respiratoire aigu sévère (génétique)</term><term>Séquence d'acides aminés</term><term>Virus du SRAS (enzymologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Aldehydes</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aldehydes</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Mutation</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Mutation</term><term>Protéines virales</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Protéines virales</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Aldéhydes</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Aldéhydes</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Binding Sites</term><term>Humans</term><term>Hydrolysis</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Molecular Structure</term><term>Protein Conformation</term><term>Protein Processing, Post-Translational</term><term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term><term>Substrate Specificity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Conformation des protéines</term><term>Données de séquences moléculaires</term><term>Humains</term><term>Hydrolyse</term><term>Maturation post-traductionnelle des protéines</term><term>Modèles moléculaires</term><term>Peptide</term><term>Aldéhyde</term><term>Inhibiteur protease</term><term>Mutation</term><term>Cysteine endopeptidases</term><term>Sites de fixation</term><term>Spectrométrie de masse MALDI</term><term>Spécificité du substrat</term><term>Structure moléculaire</term><term>Séquence d'acides aminés</term><term>Virus syndrome respiratoire aigu sévère</term><term>Résistance hydrolyse</term><term>Activité biologique</term><term>Synthèse chimique</term><term>Synthèse peptidique</term><term>In vitro</term><term>Inhibiteur enzyme</term><term>Glutamique acide(acétylthréonyl-séryl-alanyl-valyl-leucyl-1-désoxy)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with lle at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a K<sub>m</sub> of 33.8 μM and k<sub>cat</sub> of 4753 s<sup>-1</sup>. Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 10<sup>6</sup>. Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Akaji, Kenichi" sort="Akaji, Kenichi" uniqKey="Akaji K" first="Kenichi" last="Akaji">Kenichi Akaji</name></noRegion><name sortKey="Konno, Hiroyuki" sort="Konno, Hiroyuki" uniqKey="Konno H" first="Hiroyuki" last="Konno">Hiroyuki Konno</name><name sortKey="Makino, Ayumi" sort="Makino, Ayumi" uniqKey="Makino A" first="Ayumi" last="Makino">Ayumi Makino</name><name sortKey="Nosaka, Kazuto" sort="Nosaka, Kazuto" uniqKey="Nosaka K" first="Kazuto" last="Nosaka">Kazuto Nosaka</name><name sortKey="Onozuka, Mari" sort="Onozuka, Mari" uniqKey="Onozuka M" first="Mari" last="Onozuka">Mari Onozuka</name><name sortKey="Saito, Hiroyuki" sort="Saito, Hiroyuki" uniqKey="Saito H" first="Hiroyuki" last="Saito">Hiroyuki Saito</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003504 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003504 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0041831
|texte= Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
}}
| This area was generated with Dilib version V0.6.33. |  |